Abstract: Methods and compositions are provided for the treatment of virus infections in a subject which can be a human subject. The methods include administering one or more doses of a composition comprising therapeutic double-stranded RNA (tdsRNA) to a subject after active viral replication in the nasal passages of the subject. Following administration, the tdsRNA induces an enhanced and cross protective immune response to the virus or a broad-based immune response to the virus and variants thereof.

Abstract: Disclosed is a method for treating a subject that has previously been infected with SARS-COV-2 and exhibiting at least one Post COVID-19 Conditions of fatigue (PCC of fatigue) symptom. The method comprises administering to the subject a therapeutically effective amount of a composition comprising therapeutic double-stranded RNA (tdsRNA). Compositions, medicaments and delivery systems comprising tdsRNA for the treatment of PCC of fatigue are also disclosed.

Abstract: Disclosed is a method for treating endometriosis, preventing endometriosis, or ameliorating a symptom of endometriosis in a subject comprising the step of administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising as an active ingredient a therapeutic dsRNA (tdsRNA).

Abstract: Methods and compositions for treating, reducing, or preventing neuroinflammation in a subject in need thereof. The methods comprise, at least, a step of administering to a subject a therapeutically effective amount of Therapeutic Double-Stranded RNA. The compositions comprise at least a therapeutically effective amount of Therapeutic Double-Stranded RNA.

Abstract: One aspect of this disclosure is directed to a method for treating a cancer in a subject in need thereof by administering to the subject at least a first compound and a second compound together or separately. The first compound is an effective amount of a checkpoint inhibitor optionally with at least one pharmaceutically acceptable carrier. The second compound is an effective amount of an Anti-Tumor Immune Enhancer (ATIE) optionally with at least one pharmaceutically acceptable carrier. The compounds can be administered together or separately.

Abstract: The present invention relates to methods for treating a subject with myalgic encephalomyelitis/chronic fatigue syndrome symptoms comprising administering a target subject a pharmaceutical composition comprising a therapeutic dsRNA (tdsRNA).

Abstract: This disclosures relates to methods of preventing or reducing antigenic drift, viral reassortment and symptoms of wild-type and mutant influenza viruses in a host animal by determining if a host animal has been exposed to or infected by an avian influenza virus, and administering to the exposed host animal ?-interferon.

Abstract: Disclosed is a method for the synthesis of a therapeutic double-stranded RNA (tdsRNA), comprising: a) synthesizing a first single-stranded RNA (first ssRNA) in a first synthesis reaction with PNPase as the only RNA polymerase; b) synthesizing a second single-stranded RNA (second ssRNA) in a second synthesis reaction with PNPase as the only RNA polymerase; and c) hybridizing the first ssRNA with the second ssRNA to form the tdsRNA; wherein step a) and step b) are performed in any order. Also disclosed is a product produced by the method.

Abstract: Disclosed is a method for treating a cancer, such as pancreatic cancer, in a subject. The method comprises a first step of administering to the subject a standard of care therapy such as FOLFIRINOX and administering to the subject a therapeutic double stranded RNA (tdsRNA) which can be Rintatolimod.

Abstract: Disclosed is a method for treating endometriosis, preventing endometriosis, or ameliorating a symptom of endometriosis in a subject comprising the step of administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising as an active ingredient a therapeutic dsRNA (tdsRNA).

Abstract: This disclosure relates to a method of treating, preventing, or reducing a symptom of a virus infection, including a SARS-CoV-2 infection, by administering an effective amount of tdsRNA optionally with an anti-viral agent, to a subject.

Abstract: Disclosed are methods and compositions for at least preventing, treating, inhibiting, or attenuating an Ebola virus infection of a subject. The methods comprise administering an effective amount of a composition as described herein to the subject thereby at least preventing, treating, inhibiting, or attenuating the Ebola virus infection of the subject. The compositions comprise a therapeutic double-stranded RNA (tdsRNA) and additional optional components such as an Ebola antigen.

Abstract: This disclosure relates to compositions and methods for treating a subject previously infected with a virus and afflicted with post viral fatigue symptoms such as, for example, Long Covid. The compositions and methods comprise a therapeutically effective amount of a composition comprising therapeutic double-stranded RNA tdsRNA.

Abstract: One aspect of this disclosure is directed to a method for treating a cancer in a subject in need thereof by administering to the subject at least a first compound and a second compound in any order together or separately. The first compound is an effective amount of a checkpoint inhibitor optionally with at least one pharmaceutically acceptable carrier. The second compound is an effective amount of an Therapeutic Double Stranded RNA (tdsRNA) optionally with at least one pharmaceutically acceptable carrier. The compounds can be administered together or separately. Compositions for the practice of the method are also described.

Abstract: The present invention relates to methods for treating a subject with myalgic encephalomyelitis/chronic fatigue syndrome symptoms comprising administering a target subject a pharmaceutical composition comprising a therapeutic dsRNA (tdsRNA).

Abstract: One aspect of this disclosure is directed to a method for treating a cancer in a subject in need thereof by administering to the subject at least a first compound and a second compound together or separately. The first compound is an effective amount of a checkpoint inhibitor optionally with at least one pharmaceutically acceptable carrier. The second compound is an effective amount of an Anti-Tumor Immune Enhancer (ATIE) optionally with at least one pharmaceutically acceptable carrier. The compounds can be administered together or separately.

Abstract: One aspect of this disclosure is directed to a method for treating a cancer in a subject in need thereof by administering to the subject at least a first compound and a second compound together or separately. The first compound is an effective amount of a checkpoint inhibitor optionally with at least one pharmaceutically acceptable carrier. The second compound is an effective amount of an Anti-Tumor Immune Enhancer (ATIE) optionally with at least one pharmaceutically acceptable carrier. The compounds can be administered together or separately.

Abstract: A method for reducing cancerous tumors is disclosed. The method includes administering to a mammal an effective amount of epinephrine. In another embodiment, the mammal is immediately immobilized after receiving injections of epinephrine. In a most preferred embodiment, the method also includes administering an effective amount of a cardioselective adrenergic blocking agent prior to administering of epinephrine.